Treace Medical Concepts Q2 2024 GAAP EPS $(0.34) Misses $(0.29) Estimate, Sales $44.455M Beat $43.000M Estimate
Treace Medical Concepts Q2 2024 GAAP EPS $(0.34) Misses $(0.29) Estimate, Sales $44.455M Beat $43.000M Estimate
Treace医疗概念2024年第二季度GAAP EPS为$(0.34)，低于$(0.29)的预估值，销售额为4445.5万美元，高于4300万美元的预估值。
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.29) by 17.24 percent. This is a 70 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $44.455 million which beat the analyst consensus estimate of $43.000 million by 3.38 percent. This is a 5.96 percent increase over sales of $41.953 million the same period last year.
Treace Medical Concepts（纳斯达克股票代码：TMCI）公布的季度亏损为每股0.34美元，比分析师普遍预期的0.29美元（0.29美元）低17.24％。这比去年同期每股亏损0.20美元（0.20）下降了70％。该公司公布的季度销售额为4,4455万美元，比分析师普遍预期的4300万美元高出3.38％。这比去年同期的4195.3万美元销售额增长了5.96％。